{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:57:16Z","timestamp":1786978636207,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":107,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031416873","type":"print"},{"value":"9783031416880","type":"electronic"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/5584_2023_775","type":"book-chapter","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T06:01:49Z","timestamp":1685167309000},"page":"167-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Strategies for Multiple Myeloma Treatment and the Role of High-Throughput Screening for Precision Cancer Therapy"],"prefix":"10.1007","author":[{"given":"Thudzelani Takalani Austin","family":"Malise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekene Emmanuel","family":"Nweke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsa M.","family":"Takundwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascaline Fonteh","family":"Fru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak B.","family":"Thimiri Govinda Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,28]]},"reference":[{"issue":"3","key":"775_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.exphem.2014.11.004","volume":"43","author":"G An","year":"2015","unstructured":"An G, Acharya C, Deng S, Yi S, Xu Y, Qin X, Sui W, Li Z, Shi L, Zang M, Feng X, Hao M, Zou D, Zhao Y, Qi J, Cheng T, Ru K, Wang J, Tai YT, Qiu L (2015) Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment. Exp Hematol 43(3):168\u2013176.e2. https:\/\/doi.org\/10.1016\/j.exphem.2014.11.004","journal-title":"Exp Hematol"},{"issue":"3","key":"775_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/09674845.2013.11669945","volume":"70","author":"SW Andrews","year":"2013","unstructured":"Andrews SW, Kabrah S, May JE, Donaldson C, Morse HR (2013) Multiple myeloma: the bone marrow microenvironment and its relation to treatment. Br J Biomed Sci 70(3):110\u2013120. Step Publishing Ltd. https:\/\/doi.org\/10.1080\/09674845.2013.11669945","journal-title":"Br J Biomed Sci"},{"key":"775_CR3","first-page":"26","volume":"17","author":"JW Armstrong","year":"1999","unstructured":"Armstrong JW (1999) A review of high-throughput screening approaches for drug discovery. Am Biotechnol Lab 17:26\u201328","journal-title":"Am Biotechnol Lab"},{"issue":"26","key":"775_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"25","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau J-L, Facon T, Guilhot F, Doyen C, Fuzibet J-G, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto J-J, Grosbois B, Bataille R (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 25(26):2495\u20132502. www.nejm.org","journal-title":"N Engl J Med"},{"issue":"1","key":"775_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/ajco.13459","volume":"17","author":"Y Bai","year":"2021","unstructured":"Bai Y, Su X (2021) Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma. Asia-Pacific J Clin Oncol 17(1):29\u201335. Blackwell Publishing Ltd. https:\/\/doi.org\/10.1111\/ajco.13459","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"775_CR6","doi-asserted-by":"publisher","unstructured":"Battram AM, Oliver-Cald\u00e9s A, Su\u00e1rez-Lled\u00f3 M, Lozano M, Bosch i Crespo M, Mart\u00ednez-Cibri\u00e1n N, Cid J, Moreno DF, Rodr\u00edguez-Lobato LG, Urbano-Ispizua A, Fern\u00e1ndez de Larrea C (2022) T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells. Mol Ther Methods Clin Dev. https:\/\/doi.org\/10.1016\/j.omtm.2022.06.010","DOI":"10.1016\/j.omtm.2022.06.010"},{"issue":"20","key":"775_CR7","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Munshi NC (2015) Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood 125(20):3049\u20133058. https:\/\/doi.org\/10.1182\/blood-2014-11","journal-title":"Blood"},{"issue":"5","key":"775_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3324\/haematol.2009.021550","volume":"95","author":"J Blad\u00e9","year":"2010","unstructured":"Blad\u00e9 J, Teresa Cibeira M, Rosi\u00f1ol L (2010) Novel drugs for the treatment of multiple myeloma. Haematologica 95(5):702\u2013704. https:\/\/doi.org\/10.3324\/haematol.2009.021550","journal-title":"Haematologica"},{"issue":"4","key":"775_CR9","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00277-013-1924-9","volume":"93","author":"L Bolkun","year":"2014","unstructured":"Bolkun L, Lemancewicz D, Jablonska E, Kulczynska A, Bolkun-Skornicka U, Kloczko J, Dzieciol J (2014) BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma. Ann Hematol 93(4):635\u2013644. https:\/\/doi.org\/10.1007\/s00277-013-1924-9","journal-title":"Ann Hematol"},{"issue":"1","key":"775_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","volume":"98","author":"N Burwick","year":"2019","unstructured":"Burwick N, Sharma S (2019) Glucocorticoids in multiple myeloma: past, present, and future. Ann Hematol 98(1):19\u201328. Springer Verlag. https:\/\/doi.org\/10.1007\/s00277-018-3465-8","journal-title":"Ann Hematol"},{"issue":"3","key":"775_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1188\/18.CJON.263-265","volume":"22","author":"D Catamero","year":"2018","unstructured":"Catamero D (2018) Multiple myeloma: detecting genetic changes through bone marrow biopsy and the influence on care. Clin J Oncol Nurs 22(3):263\u2013265. https:\/\/doi.org\/10.1188\/18.CJON.263-265","journal-title":"Clin J Oncol Nurs"},{"issue":"6","key":"775_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.pathol.2019.05.010","volume":"51","author":"KY Chai","year":"2019","unstructured":"Chai KY, Boyke Berahmana AA, Morison IM (2019) Haematologists usually over-estimate the percentage of CD138+ plasma cells in marrow biopsies. Pathology 51(6):647\u2013648). Elsevier B.V. https:\/\/doi.org\/10.1016\/j.pathol.2019.05.010","journal-title":"Pathology"},{"issue":"7339","key":"775_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","volume":"471","author":"MA Chapman","year":"2011","unstructured":"Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB et al (2011) Initial genome sequencing and analysis of multiple myeloma. Nature 471(7339):467\u2013472. https:\/\/doi.org\/10.1038\/nature09837","journal-title":"Nature"},{"issue":"19","key":"775_CR14","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Phil D, Hawkins K, Brown J, Drayson MT, Selby PJ (2003) High-dose chemotherapy with hematopoietic stem-cell Rescue for multiple myeloma. N Engl J Med 348(19):1875\u20131883. www.nejm.org","journal-title":"N Engl J Med"},{"key":"775_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpba.2022.115036","volume":"222","author":"AM Chiorcea-Paquim","year":"2023","unstructured":"Chiorcea-Paquim AM, Oliveira-Brett AM (2023) Electrochemistry of chemotherapeutic alkylating agents and their interaction with DNA. J Pharm Biomed Anal 222:1\u201317). Elsevier B.V. https:\/\/doi.org\/10.1016\/j.jpba.2022.115036","journal-title":"J Pharm Biomed Anal"},{"key":"775_CR16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/po.20.00442","volume":"5","author":"DG Coffey","year":"2021","unstructured":"Coffey DG, Cowan AJ, DeGraaff B, Martins TJ, Curley N, Green DJ, Libby EN, Silbermann R, Chien S, Dai J, Morales A, Gooley TA, Warren EH, Becker PS (2021) High-throughput drug screening and multi-Omic analysis to guide individualized treatment for multiple myeloma. JCO Precis Oncol 5:602\u2013612. https:\/\/doi.org\/10.1200\/po.20.00442","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"775_CR17","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood-2014-10","volume":"125","author":"J Corre","year":"2015","unstructured":"Corre J, Munshi N, Herv\u00e9 H, Avet-Loiseau H (2015) Genetics of multiple myeloma: another heterogeneity level? Blood 125(12):1870\u20131876. https:\/\/doi.org\/10.1182\/blood-2014-10","journal-title":"Blood"},{"key":"775_CR18","doi-asserted-by":"crossref","unstructured":"Costa G, Ralph Engle VL, Schilling A, Massachusetts Paul Carbone B, Maryland B, Va W, Harley JB, Krall JM, Ramanan SV, Hospital U, Carbone P, Serpick A, Shadduck R, Feldstein A (1973) Melphalan and prednisone: an effective combination for the treatment of multiple myeloma. Am J Med 54(5):589\u2013599","DOI":"10.1016\/0002-9343(73)90116-2"},{"key":"775_CR19","doi-asserted-by":"publisher","first-page":"105976","DOI":"10.1016\/j.phrs.2021.105976","volume":"175","author":"F Cucchiara","year":"2022","unstructured":"Cucchiara F, Ferraro S, Luci G, Bocci G (2022) Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: preclinical and clinical data. Pharmacol Res 175:105976","journal-title":"Pharmacol Res"},{"issue":"3","key":"775_CR20","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.ijrobp.2021.07.195","volume":"111","author":"EP Damron","year":"2021","unstructured":"Damron EP, Qazilbash M, Fang P, Wu SY, Dabaja B, Rondon G, Hosing C, Champlin R, Bashir Q, Shpall EJ, Knafl M, Lee H, Manasanch EE, Patel K, Kaufman G, Thomas S, Orlowski R, Weber D, Pinnix CC, Gunther JR (2021) Radiation therapy can be safely incorporated into pre-transplant treatment regimens for patients with multiple myeloma. Int J Radiat Oncol Biol Phys 111(3):S81. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.07.195","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"775_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1182\/blood.2020004791","volume":"135","author":"N Daver","year":"2020","unstructured":"Daver N (2020) A bispecific approach to improving CAR T cells in AML. Blood 135(10):703\u2013704). Elsevier B.V. https:\/\/doi.org\/10.1182\/blood.2020004791","journal-title":"Blood"},{"key":"775_CR22","first-page":"1227","volume":"20","author":"HR de Reave","year":"2005","unstructured":"de Reave HR, Vanderkerken K (2005) The role of the bone marrow microenviroment in multiple myeloma. Histol Histopathol 20:1227\u20131250","journal-title":"Histol Histopathol"},{"key":"775_CR23","doi-asserted-by":"publisher","unstructured":"de Smedt E, Lui H, Maes K, de Veirman K, Menu E, Vanderkerken K, de Bruyne E (2018) The epigenome in multiple myeloma: impact on tumor cell plasticity and drug response. Front Oncol 8(DEC). Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fonc.2018.00566","DOI":"10.3389\/fonc.2018.00566"},{"key":"775_CR24","doi-asserted-by":"publisher","unstructured":"Diamantidis MD, Papadaki S, Hatjiharissi E (2022) Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation. Front Oncol 12. Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fonc.2022.934008","DOI":"10.3389\/fonc.2022.934008"},{"issue":"3","key":"775_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/bjh.12269","volume":"161","author":"S Dinner","year":"2013","unstructured":"Dinner S, Witteles W, Witteles R, Lam A, Arai S, Lafayette R, George TI, Schrier SL, Liedtke M (2013) The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. Br J Haematol 161(3):367\u2013372. https:\/\/doi.org\/10.1111\/bjh.12269","journal-title":"Br J Haematol"},{"issue":"18","key":"775_CR26","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","volume":"71","author":"ST Duggan","year":"2011","unstructured":"Duggan ST, Keating GM (2011) Pegylated liposomal doxorubicin A review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi\u2019s sarcoma. Drugs 71(18):2531\u20132558","journal-title":"Drugs"},{"key":"775_CR27","doi-asserted-by":"publisher","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18(7). MDPI AG. https:\/\/doi.org\/10.3390\/ijms18071414","DOI":"10.3390\/ijms18071414"},{"issue":"1","key":"775_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.23736\/S0031-0808.20.04149-X","volume":"63","author":"V Federico","year":"2021","unstructured":"Federico V, Francesca F, Gianfranco L, Maria TP, Giovanni M, Claudio C (2021) Monoclonal antibodies in multiple myeloma. Panminerva Medica 63(1):21\u201327. https:\/\/doi.org\/10.23736\/S0031-0808.20.04149-X","journal-title":"Panminerva Medica"},{"key":"775_CR29","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/asheducation-2016.1.521","volume":"1","author":"AL Garfall","year":"2016","unstructured":"Garfall AL, Stadtmauer EA (2016) Cellular and vaccine immunotherapy for multiple myeloma. Hematology Am Soc Hematol Educ Program 1:521\u2013527","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"775_CR30","first-page":"846","volume":"23","author":"A Garmpi","year":"2018","unstructured":"Garmpi A, Garmpis N, Damaskos C, Valsami S, Spartalis E, Lavaris A, Patelis N, Margonis G-A, Apostolou KG, Spartalis M, Andreatos N, Diamantis E, Tsivelekas K, Moschos MM, Nonni A, Tsourouflis G, Markatos K, Antoniou EA, Kontzoglou K et al (2018) Histone deacetylase inhibitors as a new anticancer option: how far can we go with expectations? JBUON 23(4):846\u2013861","journal-title":"JBUON"},{"key":"775_CR31","doi-asserted-by":"publisher","unstructured":"Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E (2021) The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. Int J Mol Sci 22(9). MDPI AG. https:\/\/doi.org\/10.3390\/ijms22094462","DOI":"10.3390\/ijms22094462"},{"issue":"8","key":"775_CR32","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3324\/haematol.2021.279360","volume":"107","author":"N Giesen","year":"2022","unstructured":"Giesen N, Paramasivam N, Toprak UH, Huebschmann D, Xu J, Uhrig S, Samur M, B\u00e4hr S, Fr\u00f6hlich M, Mughal SS, Mai EK, Jauch A, M\u00fcller-Tidow C, Brors B, Munshi N, Goldschmidt H, Weinhold N, Schlesner M, Raab MS (2022) Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. Haematologica 107(8):1891\u20131901. https:\/\/doi.org\/10.3324\/haematol.2021.279360","journal-title":"Haematologica"},{"issue":"6","key":"775_CR33","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/1878-0261.13191","volume":"16","author":"M Giliberto","year":"2022","unstructured":"Giliberto M, Thimiri Govinda Raj DB, Cremaschi A, Sk\u00e5nland SS, Gade A, Tj\u00f8nnfjord GE, Schjesvold F, Munthe LA, Task\u00e9n K (2022) Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically. Mol Oncol 16(6):1241\u20131258. https:\/\/doi.org\/10.1002\/1878-0261.13191","journal-title":"Mol Oncol"},{"issue":"10","key":"775_CR34","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1182\/bloodadvances.2019001425","volume":"4","author":"S Giri","year":"2020","unstructured":"Giri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SD, Ma X, Gross CP, Davidoff AJ, Neparidze N (2020) Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Adv 4(10):2245\u20132253. https:\/\/doi.org\/10.1182\/bloodadvances.2019001425","journal-title":"Blood Adv"},{"issue":"4","key":"775_CR35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/15384047.2019.1702399","volume":"21","author":"JH Gong","year":"2020","unstructured":"Gong JH, Zheng YB, Zhang MR, Wang YX, Yang SQ, Wang RH, Miao QF, Liu XJ, Zhen YS (2020) Dexamethasone enhances the antitumor efficacy of gemcitabine by glucocorticoid receptor signaling. Cancer Biol Ther 21(4):332\u2013343. https:\/\/doi.org\/10.1080\/15384047.2019.1702399","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"775_CR36","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/leu.2013.258","volume":"28","author":"AJ Greenberg","year":"2014","unstructured":"Greenberg AJ, Rajkumar S v, Therneau TM, Singh PP, Dispenzieri A, Kumar SK (2014) Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 28(2):398\u2013403. https:\/\/doi.org\/10.1038\/leu.2013.258","journal-title":"Leukemia"},{"issue":"2","key":"775_CR37","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1200\/JCO.1992.10.2.334","volume":"10","author":"WM Gregory","year":"1992","unstructured":"Gregory WM, Richards MA, Malpas JS (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10(2):334\u2013342. https:\/\/doi.org\/10.1200\/JCO.1992.10.2.334","journal-title":"J Clin Oncol"},{"issue":"10","key":"775_CR38","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.3324\/haematol.2020.247015","volume":"105","author":"A Gulla","year":"2020","unstructured":"Gulla A, Anderson KC (2020) Multiple myeloma: the (r)evolution of current therapy and a glance into the future. Haematologica 105(10):2358\u20132367. https:\/\/doi.org\/10.3324\/haematol.2020.247015","journal-title":"Haematologica"},{"key":"775_CR39","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jdsr.2021.08.006","volume":"57","author":"M Hiasa","year":"2021","unstructured":"Hiasa M, Harada T, Tanaka E, Abe M (2021) Pathogenesis and treatment of multiple myeloma bone disease. Jpn Dent Sci Rev 57:164\u2013173). Elsevier Ltd. https:\/\/doi.org\/10.1016\/j.jdsr.2021.08.006","journal-title":"Jpn Dent Sci Rev"},{"issue":"11","key":"775_CR40","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","volume":"10","author":"T Hideshima","year":"2011","unstructured":"Hideshima T, Richardson PG, Anderson KC (2011) Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Therap 10(11):2034\u20132042. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0433","journal-title":"Mol Cancer Therap"},{"issue":"10","key":"775_CR41","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1016\/j.clml.2020.05.026","volume":"20","author":"M Ho","year":"2020","unstructured":"Ho M, Goh CY, Patel A, Staunton S, O\u2019Connor R, Godeau M, Bianchi G (2020) Role of the bone marrow milieu in multiple myeloma progression and therapeutic resistance. Clin Lymphoma Myeloma Leuk 20(10):e752\u2013e768). Elsevier Inc. https:\/\/doi.org\/10.1016\/j.clml.2020.05.026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"775_CR42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"SA Holstein","year":"2017","unstructured":"Holstein SA, McCarthy PL (2017) Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs 77(5):505\u2013520). Springer International Publishing. https:\/\/doi.org\/10.1007\/s40265-017-0689-1","journal-title":"Drugs"},{"issue":"4","key":"775_CR43","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3892\/or.2019.7261","volume":"42","author":"J Hou","year":"2019","unstructured":"Hou J, Wei R, Qian J, Wang R, Fan Z, Gu C, Yang Y (2019) The impact of the bone marrow microenvironment on multiple myeloma (Review). Oncol Rep 42(4):1272\u20131282). Spandidos Publications. https:\/\/doi.org\/10.3892\/or.2019.7261","journal-title":"Oncol Rep"},{"key":"775_CR44","doi-asserted-by":"crossref","unstructured":"Jasrotia S, Gupta R, Halder A, Kumar L (2020) Cytokine profile in multiple myeloma. Cytokine 136","DOI":"10.1016\/j.cyto.2020.155271"},{"issue":"Supplement 1","key":"775_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-143045","volume":"136","author":"S Javed","year":"2020","unstructured":"Javed S, Syed TIS, Inam SHA, Abdullah SM, Najmuddin MM, Haider MZ, Fatima H, Neupane K, Sana MK, Tayyeb M, Dar AJ, Mirza MA, Anwer F (2020) Safety and adverse reactions of CAR T therapy for the treatment of multiple myeloma: a systematic review. Blood 136(Supplement 1):6\u20137. https:\/\/doi.org\/10.1182\/blood-2020-143045","journal-title":"Blood"},{"issue":"2","key":"775_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/jcp.2007.049130","volume":"61","author":"R Joshi","year":"2008","unstructured":"Joshi R, Horncastle D, Elderfield K, Lampert I, Rahemtulla A, Naresh KN (2008) Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients. J Clin Pathol 61(2):213\u2013216. https:\/\/doi.org\/10.1136\/jcp.2007.049130","journal-title":"J Clin Pathol"},{"issue":"7","key":"775_CR47","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","volume":"6","author":"S Kambhampati","year":"2022","unstructured":"Kambhampati S, Sheng Y, Huang CY, Bylsma S, Lo M, Kennedy V, Natsuhara K, Martin T, Wolf J, Shah N, Wong SW (2022) Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv 6(7):2045\u20132054. https:\/\/doi.org\/10.1182\/bloodadvances.2020004079","journal-title":"Blood Adv"},{"issue":"3","key":"775_CR48","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1365-2141.2012.09154.x","volume":"158","author":"J Kim","year":"2012","unstructured":"Kim J, Denu RA, Dollar BA, Escalante LE, Kuether JP, Callander NS, Asimakopoulos F, Hematti P (2012) Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol 158(3):336\u2013346. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09154.x","journal-title":"Br J Haematol"},{"issue":"15","key":"775_CR49","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","volume":"25","author":"SY Kristinsson","year":"2007","unstructured":"Kristinsson SY, Landgren O, Dickman PW, Derolf \u00c5R, Bj\u00f6rkholm M (2007) Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 25(15):1993\u20131999. https:\/\/doi.org\/10.1200\/JCO.2006.09.0100","journal-title":"J Clin Oncol"},{"issue":"5","key":"775_CR50","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516\u20132520. https:\/\/doi.org\/10.1182\/blood-2007-10","journal-title":"Blood"},{"issue":"5","key":"775_CR51","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Child JA, Anderson K, Barlogie B, Bataille R, Bensinger W, Blad\u00e9 J, Boccadoro M, Dalton W, Dimopoulos M, Djulbegovic B, Drayson M, Durie B, Facon T, Fonseca R, Gahrton G, Greipp P, Harousseau JL, Harrington D et al (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121(5):749\u2013757. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04355.x","journal-title":"Br J Haematol"},{"issue":"7","key":"775_CR52","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3324\/haematol.2017.174482","volume":"103","author":"C Lam","year":"2018","unstructured":"Lam C, Ferguson ID, Mariano MC, Lin YHT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103(7):1218\u20131228","journal-title":"Haematologica"},{"issue":"22","key":"775_CR53","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113(22):5412\u20135417. https:\/\/doi.org\/10.1182\/blood-2008-12-194241","journal-title":"Blood"},{"issue":"3","key":"775_CR54","doi-asserted-by":"publisher","first-page":"IJH27","DOI":"10.2217\/ijh-2020-0003","volume":"9","author":"GE Laudin","year":"2020","unstructured":"Laudin GE, Levay PF, Coetzer B (2020) Globulin fraction and albumin: globulin ratio as a predictor of mortality in a South African multiple myeloma cohort. Int J Hematol Oncol 9(3):IJH27. https:\/\/doi.org\/10.2217\/ijh-2020-0003","journal-title":"Int J Hematol Oncol"},{"issue":"9","key":"775_CR55","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.leukres.2013.05.014","volume":"37","author":"D Lemancewicz","year":"2013","unstructured":"Lemancewicz D, Bolkun L, Jablonska E, Kulczynska A, Bolkun-Skorncka U, Kloczko J, Dzieciol J (2013) The evaluation of TNF superfamily molecules in multiple myeloma patients: correlation with biological and clinical features. Leuk Res 37(9):1089\u20131093","journal-title":"Leuk Res"},{"key":"775_CR56","doi-asserted-by":"publisher","unstructured":"Liu J, Li JN, Wu H, Liu P (2022) The status and prospects of epigenetics in the treatment of lymphoma. Front Oncol 12. Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fonc.2022.874645","DOI":"10.3389\/fonc.2022.874645"},{"issue":"7","key":"775_CR57","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1158\/1078-0432.CCR-10-1066","volume":"17","author":"L L\u00f3pez-Corral","year":"2011","unstructured":"L\u00f3pez-Corral L, Guti\u00e9rrez NC, Vidriales MB, Mateos MV, Rasillo A, Garc\u00eda-Sanz R, Paiva B, San Miguel JF (2011) The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res 17(7):1692\u20131700. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1066","journal-title":"Clin Cancer Res"},{"issue":"3","key":"775_CR58","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/bjh.14686","volume":"178","author":"C Lu","year":"2017","unstructured":"Lu C, Meng S, Jin Y, Zhang W, Li Z, Wang F, Wang-Johanning F, Wei Y, Liu H, Tu H, Su D, He A, Cao X, Zhou F (2017) A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy. Br J Haematol 178(3):413\u2013426. https:\/\/doi.org\/10.1111\/bjh.14686","journal-title":"Br J Haematol"},{"key":"775_CR59","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/nrd3368","volume":"10","author":"R MacArron","year":"2011","unstructured":"MacArron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, Green DVS, Hertzberg RP, Janzen WP, Paslay JW, Schopfer U, Sittampalam GS (2011) Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 10:188\u2013195. https:\/\/doi.org\/10.1038\/nrd3368","journal-title":"Nat Rev Drug Discov"},{"key":"775_CR1001","doi-asserted-by":"publisher","unstructured":"Majumder MM, Silvennoinen R, Anttila P, Tamborero D, Eldfors S, Yadav B, Karjalainen R, Kuusanm\u00e4ki H, Lievonen J, Parsons A, Suvela M, Jantunen E, Porkka K, Heckman CA (2017) Identification of precision treatment strategies for relapsed\/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget 8(34):56338\u201356350. https:\/\/doi.org\/10.18632\/oncotarget.17630. PMID: 28915594; PMCID: PMC5593565","DOI":"10.18632\/oncotarget.17630"},{"issue":"11","key":"775_CR60","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/cmdc.202000131","volume":"15","author":"MB Martins-Teixeira","year":"2020","unstructured":"Martins-Teixeira MB, Carvalho I (2020) Antitumour anthracyclines: progress and perspectives. ChemMedChem 15(11):933\u2013948). John Wiley and Sons Ltd. https:\/\/doi.org\/10.1002\/cmdc.202000131","journal-title":"ChemMedChem"},{"issue":"10","key":"775_CR61","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1158\/1078-0432.CCR-04-1489","volume":"11","author":"G Mateo","year":"2005","unstructured":"Mateo G, Castellanos M, Rasillo A, Guti\u00e9rrez NC, Montalb\u00e1n MA, Mart\u00edn ML, Hern\u00e1ndez JM, L\u00f3pez-Berges MC, Montejano L, Blad\u00e9 J, Mateos MV, Sureda A, de La Rubia J, D\u00edaz-Mediavilla J, Pandiella A, Lahuerta JJ, Orfao A, San Miguel JF (2005) Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res 11(10):3661\u20133667. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1489","journal-title":"Clin Cancer Res"},{"issue":"3","key":"775_CR62","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hon.2300","volume":"35","author":"K Matsue","year":"2017","unstructured":"Matsue K, Matsue Y, Kumata K, Usui Y, Suehara Y, Fukumoto K, Fujisawa M, Narita K, Takeuchi M (2017) Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry. Hematol Oncol 35(3):323\u2013328. https:\/\/doi.org\/10.1002\/hon.2300","journal-title":"Hematol Oncol"},{"key":"775_CR63","doi-asserted-by":"crossref","unstructured":"Medical Research Council (1971) Myelomatosis: comparison of melphalan and cyclophosphamide therapy. Br Med J 1(5750):640\u2013641","DOI":"10.1136\/bmj.1.5750.640"},{"key":"775_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood.V130.Suppl_1.3080.3080","volume":"130","author":"N Meurice","year":"2017","unstructured":"Meurice N, Petit JL, de Campos CB, Polito AN, Lopez Armenta ID, Ahmann GJ, Bruins LA, Mikhael JR, Reeder CB, Mayo AA, Bergsagel PL, Fonseca R, Sepetov N, Romanov S, Stewart AK (2017) \u2018Direct to drug\u2019 screening as a route to individualized therapy in multiple myeloma. Blood 130:1\u20133. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.3080.3080","journal-title":"Blood"},{"issue":"7","key":"775_CR65","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.3324\/haematol.2019.243451","volume":"105","author":"F Momm","year":"2020","unstructured":"Momm F, Greil C, Sch\u00e4fer H (2020) Towards individualized radiation therapy in multiple myeloma. Haematologica 105(7):1763\u20131764). Ferrata Storti Foundation. https:\/\/doi.org\/10.3324\/haematol.2019.243451","journal-title":"Haematologica"},{"issue":"5","key":"775_CR66","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120(5):947\u2013959). American Society of Hematology. https:\/\/doi.org\/10.1182\/blood-2012-04-403733","journal-title":"Blood"},{"issue":"8","key":"775_CR67","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","volume":"103","author":"J Moreaux","year":"2004","unstructured":"Moreaux J, Legouffe E, Jourdan E, Quittet P, R\u00e8me T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103(8):3148\u20133157. https:\/\/doi.org\/10.1182\/blood-2003-06-1984","journal-title":"Blood"},{"key":"775_CR68","doi-asserted-by":"publisher","unstructured":"Moser-Katz T, Joseph NS, Dhodapkar MV, Lee KP, Boise LH (2021) Game of bones: how myeloma manipulates its microenvironment. Front Oncol 10. Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fonc.2020.625199","DOI":"10.3389\/fonc.2020.625199"},{"issue":"24","key":"775_CR69","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood.2020006540","volume":"136","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ, Martinet L (2020) Cancer immunoediting and immune dysregulation in multiple myeloma. Blood 136(24):2731\u20132740","journal-title":"Blood"},{"key":"775_CR70","first-page":"47","volume":"12","author":"EE Nweke","year":"2021","unstructured":"Nweke EE, Thimiri Govinda Raj DB (2021) Drug sensitivity and drug repurposing platform for cancer precision medicine. Cell Biol Transl Med 12:47\u201353","journal-title":"Cell Biol Transl Med"},{"issue":"1","key":"775_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medsci9010003","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, Kota V, Ajebo GH (2021) Epidemiology, staging, and management of multiple myeloma. Med Sci 9(1):3. https:\/\/doi.org\/10.3390\/medsci9010003","journal-title":"Med Sci"},{"issue":"5","key":"775_CR72","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/ejh.12009","volume":"89","author":"J Paesler","year":"2012","unstructured":"Paesler J, Gehrke I, Poll-Wolbeck SJ, Kreuzer KA (2012) Targeting the vascular endothelial growth factor in hematologic malignancies. Eur J Haematol 89(5):373\u2013384. https:\/\/doi.org\/10.1111\/ejh.12009","journal-title":"Eur J Haematol"},{"issue":"7","key":"775_CR73","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.ymthe.2019.05.015","volume":"27","author":"SR Panch","year":"2019","unstructured":"Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P, Highfill SL, Li X, Dagur P, Kochenderfer JN, Fry TJ, Mackall CL, Lee D, Shah NN, Stroncek DF (2019) Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics. Mol Ther 27(7):1275\u20131285. https:\/\/doi.org\/10.1016\/j.ymthe.2019.05.015","journal-title":"Mol Ther"},{"issue":"21","key":"775_CR74","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood.v122.21.3138.3138","volume":"122","author":"N Parrinello","year":"2013","unstructured":"Parrinello N, Romano A, Conticello C, Cavalli M, la Fauci A, Rizzo G, la Cava P, Chiarenza A, Tibullo D, Giallongo C, Palumbo GA, di Raimondo F (2013) Neutrophils of multiple myeloma are dysfunctional and immunosuppressive. Blood 122(21):3138\u20133138. https:\/\/doi.org\/10.1182\/blood.v122.21.3138.3138","journal-title":"Blood"},{"key":"775_CR75","unstructured":"Patel M (1999) An epidemiological study of multiple myeloma in Southern Africa [Doctor of Philosophy]. University of the Witwatersrand"},{"issue":"1","key":"775_CR76","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.bjp.0707373","volume":"152","author":"DA Pereira","year":"2007","unstructured":"Pereira DA, Williams JA (2007) Origin and evolution of high throughput screening. Br J Pharmacol 152(1):53\u201361. https:\/\/doi.org\/10.1038\/sj.bjp.0707373","journal-title":"Br J Pharmacol"},{"key":"775_CR77","doi-asserted-by":"crossref","unstructured":"Plosker GL, Palumbo A, Reece DE (2008) ADIS drug evaluation pegylated liposomal doxorubicin A review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 68(17):2535\u20132551","DOI":"10.2165\/0003495-200868170-00008"},{"issue":"26","key":"775_CR78","doi-asserted-by":"publisher","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","volume":"115","author":"RH Prabhala","year":"2010","unstructured":"Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC (2010) Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 115(26):5385\u20135392. https:\/\/doi.org\/10.1182\/blood-2009-10-246660","journal-title":"Blood"},{"issue":"10","key":"775_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/864058","volume":"2014","author":"SM Prideaux","year":"2014","unstructured":"Prideaux SM, Conway O\u2019Brien E, Chevassut TJ, Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet J, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE et al (2014) The genetic architecture of multiple myeloma. Advances in Hematology 2014(10):1\u201325. https:\/\/doi.org\/10.1155\/2014\/864058","journal-title":"Advances in Hematology"},{"key":"775_CR80","unstructured":"Rankapole RK, Torres Z, Sedumedi B (2011) The occurrence of multi[ple myeloam at Dr George Mukhari Hospital, Gauteng: a retrospective review (2004\u20132009). [Master of Medicine (M med) in Haematology]. University of Limpopo- Medunsa Campus"},{"issue":"1","key":"775_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/ajlm","volume":"10","author":"A Reddy","year":"2021","unstructured":"Reddy A, Rapiti N, Gounden V (2021) Comparison of 24-hour versus random urine samples for determination and quantification of Bence Jones Protein in a South African population. Afr J Lab Med 10(1):1\u20137. https:\/\/doi.org\/10.4102\/ajlm","journal-title":"Afr J Lab Med"},{"key":"775_CR82","doi-asserted-by":"publisher","unstructured":"Romano A, Storti P, Marchica V, Scandura G, Notarfranchi L, Craviotto L, di Raimondo F, Giuliani N (2021) Mechanisms of action of the new antibodies in use in multiple myeloma. Front Oncol 11. Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fonc.2021.684561","DOI":"10.3389\/fonc.2021.684561"},{"issue":"25","key":"775_CR83","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"M Roussel","year":"2014","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, Fruchart C, Stoppa AM, Gentil C, Wuilleme S, Huynh A, Hebraud B, Corre J, Chretien ML, Facon T et al (2014) Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du My\u00e9lome. J Clin Oncol 32(25):2712\u20132717. https:\/\/doi.org\/10.1200\/JCO.2013.54.8164","journal-title":"J Clin Oncol"},{"issue":"1","key":"775_CR84","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cancergencyto.2010.11.002","volume":"204","author":"JR Sawyer","year":"2011","unstructured":"Sawyer JR (2011) The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 204(1):3\u201312). Elsevier Inc. https:\/\/doi.org\/10.1016\/j.cancergencyto.2010.11.002","journal-title":"Cancer Genet"},{"key":"775_CR85","doi-asserted-by":"publisher","unstructured":"Schjesvold F, Oriol A (2021) Current and novel alkylators in multiple myeloma. Cancers 13(10). MDPI AG. https:\/\/doi.org\/10.3390\/cancers13102465","DOI":"10.3390\/cancers13102465"},{"issue":"10","key":"775_CR86","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.leukres.2012.05.010","volume":"36","author":"L Sedlarikova","year":"2012","unstructured":"Sedlarikova L, Kubiczkova L, Sevcikova S, Hajek R (2012) Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res 36(10):1218\u20131224. https:\/\/doi.org\/10.1016\/j.leukres.2012.05.010","journal-title":"Leuk Res"},{"issue":"17","key":"775_CR87","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood.2020005885","volume":"137","author":"YJ Shen","year":"2021","unstructured":"Shen YJ, Mishima Y, Shi J, Sklavenitis-Pistofidis R, Redd RA, Moschetta M, Manier S, Roccaro AM, Sacco A, Tai Y-T, Mercier F, Kawano Y, Su NK, Berrios B, Doench JG, Root DE, Michor F, Scadden DT, Ghobrial IM (2021) Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood 137(17):2361\u20132372. https:\/\/www.r-project.org\/","journal-title":"Blood"},{"issue":"21","key":"775_CR88","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1182\/bloodadvances.2019000370","volume":"3","author":"S Sidana","year":"2019","unstructured":"Sidana S, Shah N (2019) CAR T-cell therapy: is it prime time in myeloma? Blood Adv 3(21):3473\u20133480). American Society of Hematology. https:\/\/doi.org\/10.1182\/bloodadvances.2019000370","journal-title":"Blood Adv"},{"key":"775_CR89","doi-asserted-by":"crossref","unstructured":"Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10. http:\/\/www.biomedcentral.com\/1471-2407\/10\/337","DOI":"10.1186\/1471-2407-10-337"},{"issue":"6","key":"775_CR90","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ymthe.2019.04.001","volume":"27","author":"C Sommer","year":"2019","unstructured":"Sommer C, Boldajipour B, Kuo TC, Bentley T, Sutton J, Chen A, Geng T, Dong H, Galetto R, Valton J, Pertel T, Juillerat A, Gariboldi A, Pascua E, Brown C, Chin SM, Sai T, Ni Y, Duchateau P et al (2019) Preclinical evaluation of allogeneic CAR T cells targeting BCMA for the treatment of multiple myeloma. Mol Ther 27(6):1126\u20131138. https:\/\/doi.org\/10.1016\/j.ymthe.2019.04.001","journal-title":"Mol Ther"},{"key":"775_CR91","doi-asserted-by":"publisher","unstructured":"Sritharan S, Sivalingam N (2021) A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci 278. Elsevier Inc. https:\/\/doi.org\/10.1016\/j.lfs.2021.119527","DOI":"10.1016\/j.lfs.2021.119527"},{"key":"775_CR92","doi-asserted-by":"publisher","unstructured":"\u0160tifter S, Babarovi\u0107 E, Valkovi\u0107 T, Seili-Bekafigo I, \u0160temberger C, Na\u010dinovi\u0107 A, Lu\u010din K, Jonji\u0107 N (2010) Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma. Diagn Pathol 5(1). https:\/\/doi.org\/10.1186\/1746-1596-5-30","DOI":"10.1186\/1746-1596-5-30"},{"key":"775_CR93","doi-asserted-by":"publisher","unstructured":"Tai YT, Cho SF, Anderson KC (2018) Osteoclast immunosuppressive effects in multiple myeloma: role of programmed cell death ligand 1. Front Immunol 9(Aug). Frontiers Media S.A. https:\/\/doi.org\/10.3389\/fimmu.2018.01822","DOI":"10.3389\/fimmu.2018.01822"},{"key":"775_CR94","unstructured":"The Global Cancer Observatory (2020, December) Multiple myeloma. International Agency for Research on Cancer. https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/35-Multiple-myeloma-fact-sheet.pdf"},{"key":"775_CR95","doi-asserted-by":"crossref","unstructured":"Thimiri Govinda Raj DB, Giliberto M, Cremaschi A, Skanland SS, Gade A, Tj\u00f8nnfjord GE, Schjesvold F, Munthe LA, Tasken K (2018a) Drug sensitivity screening on multiple myeloma for precision cancer therapy. Blood 132(Supplement 1)","DOI":"10.1182\/blood-2018-99-110669"},{"key":"775_CR96","unstructured":"Thimiri Govinda Raj DB, Giliberto M, Sk\u00e5nland SS (2018b) Drug sensitivity screening in multiple myeloma (MM) for precision cancer therapy. https:\/\/wkhealth.force.com\/lwwonline\/s\/topic\/0TO0V000001YgLZWA0\/lww-online?tabset-"},{"issue":"10","key":"775_CR97","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3324\/haematol.2012.081083","volume":"98","author":"S van Wier","year":"2013","unstructured":"van Wier S, Braggio E, Baker A, Ahmann G, Levy J, Carpten JD, Fonseca R (2013) Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica 98(10):1586\u20131592. https:\/\/doi.org\/10.3324\/haematol.2012.081083","journal-title":"Haematologica"},{"key":"775_CR98","doi-asserted-by":"publisher","unstructured":"Verheye E, Melgar JB, Deschoemaeker S, Raes G, Maes A, de Bruyne E, Menu E, Vanderkerken K, Laoui D, de Veirman K (2022) Dendritic cell-based immunotherapy in multiple myeloma: challenges, opportunities, and future directions. Int J Mol Sci 23(2). MDPI. https:\/\/doi.org\/10.3390\/ijms23020904","DOI":"10.3390\/ijms23020904"},{"issue":"3","key":"775_CR99","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/15592294.2016.1273308","volume":"12","author":"S Wang","year":"2017","unstructured":"Wang S, Wu W, Claret FX (2017) Mutual regulation of microRNAs and DNA methylation in human cancers. Epigenetics 12(3):187\u2013197). Taylor & Francis Inc. https:\/\/doi.org\/10.1080\/15592294.2016.1273308","journal-title":"Epigenetics"},{"key":"775_CR100","doi-asserted-by":"publisher","unstructured":"Wang X, Qi Y, Li H, Liu F, Cao J, Chen W, Wang Y, Qi K, Yan Z, Zhu F, Li Z, Cheng H, Xu K (2022) Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed\/refractory multiple myeloma treated with CAR-T therapy. Front Immunol:13. https:\/\/doi.org\/10.3389\/fimmu.2022.943004","DOI":"10.3389\/fimmu.2022.943004"},{"key":"775_CR101","doi-asserted-by":"publisher","unstructured":"Wong TW, Kita H, Hanson CA, Walters DK, Arendt BK, Jelinek DF (2013) Induction of malignant plasma cell proliferation by eosinophils. PLoS One 8(7). https:\/\/doi.org\/10.1371\/journal.pone.0070554","DOI":"10.1371\/journal.pone.0070554"},{"key":"775_CR102","doi-asserted-by":"publisher","unstructured":"Wudhikarn K, Wills B, Lesokhin AM (2020) Monoclonal antibodies in multiple myeloma: current and emerging targets and mechanisms of action. Best Pract Res Clin Haematol 33(1). Bailliere Tindall Ltd. https:\/\/doi.org\/10.1016\/j.beha.2020.101143","DOI":"10.1016\/j.beha.2020.101143"},{"issue":"2","key":"775_CR103","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1182\/bloodadvances.2021004992","volume":"6","author":"Y Yan","year":"2022","unstructured":"Yan Y, Qin X, Liu J, Fan H, Yan W, Liu L, Du C, Yu Z, Xu Y, Hao M, Deng S, Sui W, Lyu R, Liu W, Wang Q, Zou D, Hu L, Wang J, Tai YT et al (2022) Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH. Blood Adv 6(2):441\u2013451. https:\/\/doi.org\/10.1182\/bloodadvances.2021004992","journal-title":"Blood Adv"},{"key":"775_CR104","doi-asserted-by":"publisher","unstructured":"Yang WC, Lin SF (2015) Mechanisms of drug resistance in relapse and refractory multiple myeloma. BioMed Res Int 2015). Hindawi Publishing Corporation. https:\/\/doi.org\/10.1155\/2015\/341430","DOI":"10.1155\/2015\/341430"},{"issue":"3","key":"775_CR105","doi-asserted-by":"publisher","first-page":"244.e1","DOI":"10.1016\/j.jtct.2020.12.009","volume":"27","author":"BA Zannetti","year":"2021","unstructured":"Zannetti BA, Saraceni F, Cellini C, Fabbri E, Monaco F, Guarini A, Laszlo D, Martino M, Olivieri A, Imola M, Tosi P, Chiarucci M, Zuffa E, Lanza F (2021) Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a Multicenter Retrospective Study. Transplantat Cell Therapy 27(3):244.e1\u2013244.e8. https:\/\/doi.org\/10.1016\/j.jtct.2020.12.009","journal-title":"Transplantat Cell Therapy"},{"issue":"17","key":"775_CR106","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","volume":"114","author":"Y Zheng","year":"2009","unstructured":"Zheng Y, Cai Z, Wang S, Zhang X, Qian J, Hong S, Li H, Wang M, Yang J, Yi Q (2009) Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114(17):3625\u20133628. https:\/\/doi.org\/10.1182\/blood-2009-05-220285","journal-title":"Blood"}],"container-title":["Advances in Experimental Medicine and Biology","Cell Biology and Translational Medicine, Volume 20"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2023_775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T08:13:41Z","timestamp":1692864821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/5584_2023_775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9783031416873","9783031416880"],"references-count":107,"URL":"https:\/\/doi.org\/10.1007\/5584_2023_775","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"28 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}